Global Endocrinology Drugs Market 2016-2020

内分泌系治療薬の世界市場:糖尿病薬、テストステロン補充療法、ヒト成長ホルモン、甲状腺ホルモン障害治療薬

◆タイトル:Global Endocrinology Drugs Market 2016-2020
◆商品コード:IRTNTR9023
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年4月19日
◆ページ数:118
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、内分泌系治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、内分泌系治療薬の世界市場規模及び予測、用途別分析(糖尿病薬、テストステロン補充療法、ヒト成長ホルモン、甲状腺ホルモン障害治療薬)、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

About Endocrinology Drugs
Endocrinology deals with the study of the endocrine system, including the biochemical and physiological functions of the hormones, cells, and tissues of the endocrine glands. Endocrine disorders can be broadly subdivided into three categories: endocrine gland hyposecretion, which causes hormone deficiency, endocrine gland hypersecretion, which causes excess hormone secretion, and tumors in the endocrine gland. The endocrine disorders considered for the present report include diabetes, human growth hormone deficiency, thyroid disorders, and male hypogonadism.

Technavio’s analysts forecast the global endocrinology drugs market to grow at a CAGR of 6.69% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global endocrinology drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat and prevent type 1 and type 2 diabetes, human growth hormone deficiency, hypogonadism, and thyroid gland disorders.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Endocrinology Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie Inc.
• AstraZeneca PLC
• Eli Lilly and Co.
• Merck & Co
• Novo Nordisk AS
• Sanofi SA

[Other prominent vendors]
• Acerus Pharmaceuticals
• Acrux DDS
• Adocia
• Æterna Zentaris
• Akros Pharma
• Allergan
• Amgen
• Antares Pharma
• Ascendis Pharma
• Astellas Pharma
• Baxalta
• Bayer HealthCare Pharmaceuticals
• BHV Pharma
• Biocon
• Biodel
• Boehringer Ingelheim
• ChipScreen Biosciences
• Clarus Therapeutics
• ConjuChem
• Critical Pharmaceuticals
• CureDm
• CymaBay Therapeutics
• Daiichi Sankyo
• Dance Biopharm
• DiaMedica
• Diamyd Therapeutics
• Diasome Pharmaceuticals
• DiaVacs
• Dong-A ST
• Eisai
• Elcelyx Therapeutics
• Endo Pharmaceuticals
• Exsulin
• Ferring Pharmaceuticals
• Gan & Lee Pharmaceuticals
• Genentech
• Generex
• Genexine
• Genfit
• GSK
• HanAll BioPharma
• Hanmi Pharmaceutical
• Hua Medicine
• ILTOO Pharma
• Intarcia Therapeutics
• InteKrin Therapeutics
• Intrexon
• Ionis Pharmaceuticals
• Ipe
• Islet Sciences
• Janssen Pharmaceuticals
• Japan Tobacco
• Juniper Pharmaceuticals
• Kadmon Corporation
• Kamada
• KinDex Pharmaceuticals
• Kissei Pharmaceutical
• Kotobuki
• Lexicon Pharmaceuticals
• LG Life Sciences
• Ligand Pharmaceuticals
• Lipocine
• Living Cell Technologies
• MacroGenics
• MannKind
• MedImmune
• Melior Pharmaceuticals
• Metabolic Solutions Development Company
• MetP Pharma
• Mitsubishi Tanabe Pharma
• Mylan
• NGM Biopharmaceuticals
• Novartis
• NuSirt Biopharma
• OPKO Biologics
• Oramed Pharmaceuticals
• Osiris Therapeutics
• Peptron
• Perle Biosciences
• Pfizer
• PhaseBio Pharmaceuticals
• Poxel
• ProStrakan Group
• REGiMMUNE
• Repros Therapeutics
• Roche
• Sanwa Kagaku Kenkyusho
• Sirona Biochem
• Strongbridge Biopharma
• Takeda Pharmaceuticals
• TesoRx Pharma
• Teva Pharmaceutical
• Theracos
• Theratechnologies
• Toleranzia
• Tolerion
• Transition Therapeutics
• VeroScience
• Versartis
• vTv Therapeutics
• XBiotech
• Xeris Pharmaceuticals
• XOMA

[Market driver]
• Increase in prevalence of endocrine hormone-related diseases
• For a full, detailed list, view our report

[Market challenge]
• Generic erosion
• For a full, detailed list, view our report

[Market trend]
• Increase in outsourcing
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Key buying criteria

PART 06: Pipeline portfolio

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by application

PART 09: Global diabetes drugs market
• Introduction
• Market overview
• Market drivers
• Market challenges
• Market trends
• Vendor analysis of global diabetes drugs market

PART 10: Global testosterone replacement therapy market
• Introduction
• Market overview
• Market drivers
• Market challenges
• Market trends
• Vendor analysis of global testosterone replacement therapy market

PART 11: Global human growth hormone market
• Introduction
• Market overview
• Market drivers
• Market challenges
• Market trends
• Vendor analysis of global human growth hormone market

PART 12: Global thyroid hormone disorder drugs market
• Market overview
• Market drivers
• Market challenges
• Market trends
• Vendor analysis of global thyroid disorder drugs market

PART 13: Geographical segmentation
• Global endocrinology drugs market by geographical segmentation 2015-2020
• Endocrinology drugs market in Americas
• Endocrinology drugs market in EMEA
• Endocrinology drugs market in APAC

PART 14: Market drivers
• Increase in prevalence of endocrine hormone-related diseases
• Promising drug pipeline
• Advances in drug delivery technology
• Stringent regulatory conditions for biosimilar drugs

PART 15: Impact of drivers

PART 16: Market challenges
• Generic erosion
• Side effects and associated risks
• Rising concerns in scientific community
• Low diagnosis rate

PART 17: Impact of drivers and challenges

PART 18: Market trends
• Development of drugs with novel mechanism and technologies
• Strategic alliances and M&A
• Increased awareness
• Increase in outsourcing

PART 19: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Novo Nordisk
• Sanofi
• Merck
• Eli Lilly
• AstraZeneca
• AbbVie
• Other prominent vendors

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for endocrinology drugs
Exhibit 03: Pipeline portfolio: Global diabetes drugs market
Exhibit 04: Pipeline portfolio: Global thyroid disorder drugs market
Exhibit 05: Pipeline portfolio: Global human growth hormone drugs market
Exhibit 06: Pipeline portfolio: Global testosterone drugs market
Exhibit 07: Global endocrinology drugs market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Market segmentation of global endocrinology drugs market by application
Exhibit 10: Global endocrinology drugs market: YoY growth and revenue based on application 2015-2020
Exhibit 11: Global diabetes market by type of disease 2015
Exhibit 12: Top-selling diabetes drugs based on sales 2015 ($ billions)
Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 15: Market share analysis of vendors in global diabetes drugs market
Exhibit 16: Global testosterone replacement therapy market 2015-2020 ($ billions)
Exhibit 17: Global human growth hormone market 2015-2020 ($ billions)
Exhibit 18: Global human growth hormone market 2015-2020 ($ billions)
Exhibit 19: Segmentation of global endocrinology drugs market based on geography 2015
Exhibit 20: Global endocrinology drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 21: Global endocrinology drugs market by geography 2015-2020
Exhibit 22: Endocrinology drugs market in Americas 2015-2020 ($ billions)
Exhibit 23: Endocrinology drugs market in EMEA 2015-2020 ($ billions)
Exhibit 24: Endocrinology drugs market in APAC 2015-2020 ($ billions)
Exhibit 25: Global endocrinology drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 26: Impact of drivers
Exhibit 27: Impact of drivers and challenges
Exhibit 28: Revenues from the sales of top seven products in type 2 diabetes market 2012-2014 ($ billions)
Exhibit 29: Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($ billions)
Exhibit 30:
Exhibit 31: Novo Nordisk: Geographical segmentation of human insulins 2015
Exhibit 32: Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions)
Exhibit 33: Geographical segmentation of Levemir 2015
Exhibit 34: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($ billions)
Exhibit 35: Novo Nordisk: Revenue of NovoLog/NovoRapid by geography 2015
Exhibit 36: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($ billions)
Exhibit 37: Novo Nordisk: Geographical split of revenues of NovoMix 2015
Exhibit 38: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 39: Novo Nordisk: YoY revenue and growth rate of Victoza 2013-2015 ($ billions)
Exhibit 40: Geographical segmentation of Victoza 2015
Exhibit 41: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and PrandiMet 2012-2014 ($ millions)
Exhibit 42: Novo Nordisk: YoY growth rate and revenue of Norditropin 2013-2015 ($ billions)
Exhibit 43: Novo Nordisk: Revenue of Norditropin by geography 2015
Exhibit 44: Novo Nordisk: Key takeaways
Exhibit 45: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
Exhibit 46: Sanofi: Geographical segmentation of Lantus by revenue 2015
Exhibit 47: Sanofi: YoY revenue and growth rate of Amaryl 2013-2015 ($ millions)
Exhibit 48: Sanofi: Amaryl geographical segmentation by revenue 2015
Exhibit 49: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ million)
Exhibit 50: Sanofi: Geographical segmentation of Toujeo by revenue 2015 (%)
Exhibit 51: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
Exhibit 52: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
Exhibit 53: Sanofi: Key takeaways
Exhibit 54: Merck: YoY revenue and growth rate of Januvia 2013-2015 ($ billions)
Exhibit 55: Merck: YoY revenue and growth rate of Januvia 2013-2015 ($ billions)
Exhibit 56: Merck: Key takeaways
Exhibit 57: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
Exhibit 58: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
Exhibit 59: Eli Lilly: YoY revenue and growth rate of Trajenta and Jentadueto 2012-2015 ($ billions)
Exhibit 60: Eli Lilly: YoY revenue of Trulicity 2014-2015 ($ millions)
Exhibit 61: Eli Lilly: Trulicity geographical segmentation by revenue 2015
Exhibit 62: Eli Lilly: Key takeaways
Exhibit 63: AstraZeneca: YoY revenue and growth rate of Farxiga 2013-2015 ($ millions)
Exhibit 64: AstraZeneca: Geographical segmentation of Farxiga/Forxiga by revenue 2015
Exhibit 65: AstraZeneca: YoY revenue and growth rate of Byetta 2013-2015 ($ million)
Exhibit 66: AstraZeneca: YoY revenue and growth rate of Bydureon 2013-2015 ($ millions)
Exhibit 67: AstraZeneca: YoY revenue and growth rate of Kombiglyze/Komboglyze/Onglyza 2013-2015 ($ millions)
Exhibit 68: AstraZeneca: Key takeaways
Exhibit 69: AbbVie: YoY revenue and growth rate of AndroGel 2013-2015 ($ millions)
Exhibit 70: AbbVie: YoY revenue and growth rate of Synthroid 2013-2015 ($ millions)
Exhibit 71: AbbVie: Key takeaways



【掲載企業】

AbbVie Inc., AstraZeneca PLC, Eli Lilly and Co., Merck & Co, Novo Nordisk AS, Sanofi SA, Acerus Pharmaceuticals, Acrux DDS, Adocia, Æterna Zentaris, Akros Pharma, Allergan, Amgen, Antares Pharma, Ascendis Pharma, Astellas Pharma, Baxalta, Bayer HealthCare Pharmaceuticals, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, ChipScreen Biosciences, Clarus Therapeutics, ConjuChem, Critical Pharmaceuticals, CureDm, CymaBay Therapeutics, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Endo Pharmaceuticals, Exsulin, Ferring Pharmaceuticals, Gan & Lee Pharmaceuticals, Genentech, Generex, Genexine, Genfit, GSK, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, ILTOO Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Ipe, Islet Sciences, Janssen Pharmaceuticals, Japan Tobacco, Juniper Pharmaceuticals, Kadmon Corporation, Kamada, KinDex Pharmaceuticals, Kissei Pharmaceutical, Kotobuki, Lexicon Pharmaceuticals, LG Life Sciences, Ligand Pharmaceuticals, Lipocine, Living Cell Technologies, MacroGenics, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, MetP Pharma, Mitsubishi Tanabe Pharma, Mylan, NGM Biopharmaceuticals, Novartis, NuSirt Biopharma, OPKO Biologics, Oramed Pharmaceuticals, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, ProStrakan Group, REGiMMUNE, Repros Therapeutics, Roche, Sanwa Kagaku Kenkyusho, Sirona Biochem, Strongbridge Biopharma, Takeda Pharmaceuticals, TesoRx Pharma, Teva Pharmaceutical, Theracos, Theratechnologies, Toleranzia, Tolerion, Transition Therapeutics, VeroScience, Versartis, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA.

【資料のキーワード】

内分泌系治療薬、糖尿病薬、テストステロン補充療法、ヒト成長ホルモン、甲状腺ホルモン障害治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[内分泌系治療薬の世界市場:糖尿病薬、テストステロン補充療法、ヒト成長ホルモン、甲状腺ホルモン障害治療薬] (Global Endocrinology Drugs Market 2016-2020 / IRTNTR9023)販売に関する免責事項
[内分泌系治療薬の世界市場:糖尿病薬、テストステロン補充療法、ヒト成長ホルモン、甲状腺ホルモン障害治療薬] (Global Endocrinology Drugs Market 2016-2020 / IRTNTR9023)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆